Onxeo develops innovative oncology drugs targeting tumor intracellular functions through unique mechanisms of action, notably in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage, first-in-class or disruptive compounds from translational research to clinical proof-of-concept.
AsiDNA™ is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a unique decoy & agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the unique properties of AsiDNA™, notably its ability to oppose and even reverse tumor resistance to PARP inhibitors regardless of the genetic mutation status, and its strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. AsiDNA™ is currently being evaluated in combination with carboplatin, and carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments in the DRIIV-1b I study .
AsiDNA™ is the first compound generated from platON™, the Company’s proprietary chemistry platform of decoy oligonucleotides dedicated to generate new innovative leads and broaden Onxeo’s pipeline.
A new compound, OX401, is beign evaluated in preclinical studies. OX401 aims to be a next-generation PARP inhibitor which would not induced resistance but activate the immune response.
belinostat, is an HDAC inhibitor (epigenetics), already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo’s partner under the name Beleodaq® (belinostat IV form).